MedTrace Logo

Trunk Restraint in Multiple Sclerosis

NCT06982833 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-05-21

No results posted yet for this study

Summary

This study examined the effect of trunk restraint on upper extremity functionality in patients with Multiple Sclerosis (MS).The study included 66 MS patients over the age of 18 and 30 healthy individuals. Participants' upper extremity functions were assessed. Their trunks were then restrained and their upper extremity functions were assessed again. The patients' level of disability (EDSS), trunk control (Trunk Impairment Scale - TIS), upper extremity functionality (Nine Hole Peg Test- 9HPT), were evaluated.

Conditions

Interventions

OTHER

Trunk restraint

Participants were seated in a chair with a standard sitting height of 26 centimeters. After completing the 9-Hole Peg Test with their trunks free on a table of appropriate height so that their trunks would not flexion, they were secured to the chair crosswise in front of their chest with the help of a non-elastic but firm enough belt that would not cause discomfort to the person. Participants completed the 9-DPT with their trunks constrained.

Sponsors & Collaborators

  • Zonguldak Bulent Ecevit University

    lead OTHER

Principal Investigators

  • Güngör Beyza Özvar Şenöz, PhD · Yuksek Ihtisas University

  • Bilge Piri Çınar, Assoc. Prof. · Samsun University

  • Mustafa Açıkgöz, Assoc. Prof · Zonguldak Bulent Ecevit University

  • Nursena Ceylan · Zonguldak Bulent Ecevit University

  • Arzucan Toksal Uçar · Zonguldak Bulent Ecevit University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-10
Primary Completion
2025-04-10
Completion
2025-04-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06982833 on ClinicalTrials.gov